232 related articles for article (PubMed ID: 31915140)
1. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia.
Huot JR; Novinger LJ; Pin F; Bonetto A
Dis Model Mech; 2020 Jan; 13(1):. PubMed ID: 31915140
[TBL] [Abstract][Full Text] [Related]
2. MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer.
Huot JR; Pin F; Essex AL; Bonetto A
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540821
[TBL] [Abstract][Full Text] [Related]
3. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
[TBL] [Abstract][Full Text] [Related]
4. Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.
Huot JR; Novinger LJ; Pin F; Narasimhan A; Zimmers TA; O'Connell TM; Bonetto A
JCI Insight; 2020 May; 5(9):. PubMed ID: 32298240
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
6. Metastatic or xenograft colorectal cancer models induce divergent anabolic deficits and expression of pro-inflammatory effectors of muscle wasting in a tumor-type-dependent manner.
Kim HG; Huot JR; Pin F; Belcher DJ; Bonetto A; Nader GA
J Appl Physiol (1985); 2022 Dec; 133(6):1273-1283. PubMed ID: 36201323
[TBL] [Abstract][Full Text] [Related]
7. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
8. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia.
Pin F; Barreto R; Kitase Y; Mitra S; Erne CE; Novinger LJ; Zimmers TA; Couch ME; Bonewald LF; Bonetto A
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):685-700. PubMed ID: 30009406
[TBL] [Abstract][Full Text] [Related]
9. Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy.
Cerquone Perpetuini A; Re Cecconi AD; Chiappa M; Martinelli GB; Fuoco C; Desiderio G; Castagnoli L; Gargioli C; Piccirillo R; Cesareni G
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):727-746. PubMed ID: 29781585
[TBL] [Abstract][Full Text] [Related]
10. Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3.
Chen L; Xu W; Yang Q; Zhang H; Wan L; Xin B; Zhang J; Guo C
Pharmacol Res; 2020 Aug; 158():104871. PubMed ID: 32413482
[TBL] [Abstract][Full Text] [Related]
11. Physiological characterization of a mouse model of cachexia in colorectal liver metastases.
Murphy KT; Struk A; Malcontenti-Wilson C; Christophi C; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2013 May; 304(10):R854-64. PubMed ID: 23485871
[TBL] [Abstract][Full Text] [Related]
12. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway.
Shen Q; Kuang JX; Miao CX; Zhang WL; Li YW; Zhang XW; Liu X
Phytomedicine; 2022 Jan; 95():153858. PubMed ID: 34861585
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of heat shock protein (HSP) 90 reverses signal transducer and activator of transcription (STAT) 3-mediated muscle wasting in cancer cachexia mice.
Niu M; Song S; Su Z; Wei L; Li L; Pu W; Zhao C; Ding Y; Wang J; Cao W; Gao Q; Wang H
Br J Pharmacol; 2021 Nov; 178(22):4485-4500. PubMed ID: 34265073
[TBL] [Abstract][Full Text] [Related]
14. Ursolic acid alleviates cancer cachexia by inhibiting STAT3 signaling pathways in C2C12 myotube and CT26 tumor-bearing mouse model.
Chen L; Chen Y; Wang M; Lai L; Zheng L; Lu H
Eur J Pharmacol; 2024 Apr; 969():176429. PubMed ID: 38423241
[TBL] [Abstract][Full Text] [Related]
15. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
16. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.
Bonetto A; Aydogdu T; Kunzevitzky N; Guttridge DC; Khuri S; Koniaris LG; Zimmers TA
PLoS One; 2011; 6(7):e22538. PubMed ID: 21799891
[TBL] [Abstract][Full Text] [Related]
17. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA
Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613
[TBL] [Abstract][Full Text] [Related]
18. Muscle oxidative capacity during IL-6-dependent cancer cachexia.
White JP; Baltgalvis KA; Puppa MJ; Sato S; Baynes JW; Carson JA
Am J Physiol Regul Integr Comp Physiol; 2011 Feb; 300(2):R201-11. PubMed ID: 21148472
[TBL] [Abstract][Full Text] [Related]
19. PGC1α overexpression preserves muscle mass and function in cisplatin-induced cachexia.
Huot JR; Pin F; Chatterjee R; Bonetto A
J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2480-2491. PubMed ID: 35903870
[TBL] [Abstract][Full Text] [Related]
20. Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response.
Guo D; Wang C; Wang Q; Qiao Z; Tang H
Oncotarget; 2017 Jun; 8(24):39640-39648. PubMed ID: 28489606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
